Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer’s Disease ; volume:37 ; number:8 ; day:20 ; month:7 ; year:2023 ; pages:671-677 ; date:8.2023
CNS drugs ; 37, Heft 8 (20.7.2023), 671-677, 8.2023
- Creator
-
Leisher, Solana
Bohorquez, Adriana
Gay, Marcus
Garcia, Victoria
Jones, Renarda
Baldaranov, Dobri
Rafii, Michael S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-023-01021-8
- URN
-
urn:nbn:de:101:1-2023110414250418632396
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Leisher, Solana
- Bohorquez, Adriana
- Gay, Marcus
- Garcia, Victoria
- Jones, Renarda
- Baldaranov, Dobri
- Rafii, Michael S.
- SpringerLink (Online service)
Other Objects (12)
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Amyloid-Precursor-Protein-lowering small molecules for disease modifying therapy of Alzheimer's disease
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer’s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness
Amyloid PET imaging: applications beyond Alzheimer’s disease
Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention
Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Amyloid-Precursor-Protein-lowering small molecules for disease modifying therapy of Alzheimer's disease
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer’s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness
Amyloid PET imaging: applications beyond Alzheimer’s disease
Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention
Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
Amyloid-Precursor-Protein-lowering small molecules for disease modifying therapy of Alzheimer's disease
News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer’s disease in 2023
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
Critical assessment of anti-amyloid-β monoclonal antibodies effects in Alzheimer’s disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness
Amyloid PET imaging: applications beyond Alzheimer’s disease
Blood Derived Amyloid Biomarkers for Alzheimer’s Disease Prevention